Romidepsin is a targeted therapy medicine used in the treatment of Peripheral T Cell Lymphoma (PTCL) and Cutaneous T Cell Lymphoma (CTCL). Romidepsin is isolated
from a bacterium called Chromobacterium violaceum and is thought to reduce the growth and division of lymphoma cells by inhibiting the process involved in the regulation in these lymphomas.
Romidepsin is given by intravenous infusion which means it goes directly into the vein through a needle in your arm or through a central line if you have one in place. Romidepsin
is given every week for three weeks then a week off the medicine to complete a four-week cycle. Number of cycles given will depend on your subtype and disease status of lymphoma.
Romidepsin may have the following side effects:
• Low blood counts
Romidepsin is approved by the TGA and currently awaiting approval to be listed on the PBS however access to Romidepsin can be found in clinical trials around Australia and by access programs through the pharmaceutical company.